HC Wainwright Brokers Reduce Earnings Estimates for Surrozen

Surrozen, Inc. (NASDAQ:SRZN) – Equities research analysts at HC Wainwright lowered their Q4 2025 earnings estimates for Surrozen in a research report issued to clients and investors on Monday, November 10th. HC Wainwright analyst M. Caufield now expects that the company will earn ($1.23) per share for the quarter, down from their prior forecast of ($1.15). The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. HC Wainwright also issued estimates for Surrozen’s FY2026 earnings at ($4.79) EPS, FY2027 earnings at ($4.91) EPS, FY2028 earnings at ($5.41) EPS and FY2029 earnings at ($5.80) EPS.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The business had revenue of $0.98 million for the quarter.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Surrozen has a consensus rating of “Hold” and an average target price of $38.50.

Surrozen Stock Up 2.7%

Shares of NASDAQ SRZN opened at $12.12 on Wednesday. Surrozen has a 12 month low of $5.90 and a 12 month high of $18.17. The company has a market cap of $103.87 million, a P/E ratio of -0.54 and a beta of 0.64. The business’s 50 day moving average is $12.79 and its two-hundred day moving average is $10.54.

Institutional Investors Weigh In On Surrozen

Several institutional investors and hedge funds have recently bought and sold shares of the business. Stempoint Capital LP lifted its holdings in shares of Surrozen by 185.1% during the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after acquiring an additional 445,713 shares during the period. RA Capital Management L.P. increased its stake in Surrozen by 140.3% in the first quarter. RA Capital Management L.P. now owns 679,130 shares of the company’s stock valued at $7,919,000 after acquiring an additional 396,550 shares during the period. 5AM Venture Management LLC acquired a new position in Surrozen in the first quarter worth about $3,615,000. Vivo Capital LLC bought a new position in Surrozen during the first quarter worth about $3,032,000. Finally, Driehaus Capital Management LLC bought a new position in Surrozen during the first quarter worth about $2,390,000. Institutional investors own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.